Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024

This “Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Peripheral Arterial Disease (PAD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peripheral Arterial Disease (PAD): Understanding

Peripheral Arterial Disease (PAD): Overview

Peripheral Arterial Disease (PAD) is a circulatory condition where narrowed arteries reduce blood flow to the limbs, commonly affecting the legs. It is primarily caused by atherosclerosis, where fatty deposits build up in the artery walls, restricting blood flow. Symptoms include leg pain during walking (claudication), numbness, or non-healing wounds. PAD increases the risk of heart attack, stroke, and can lead to severe complications like limb amputation if untreated. It is a condition characterized by the narrowing or blockage of peripheral arteries, most commonly in the legs, due to atherosclerosis.

Peripheral Arterial Disease (PAD) typically develops over time and may go unnoticed in its early stages, but as it progresses, symptoms become more apparent. Common symptoms include Intermittent Claudication, Leg Numbness or Weakness, Coldness in the Lower Leg or Foot, Sores or Wounds on Toes, Feet, or Legs, Color Changes in the Skin, Weak or Absent Pulse in the Legs or Feet and Slower Growth of Toenails. Peripheral Arterial Disease (PAD) risk factors primarily include lifestyle and health conditions that contribute to atherosclerosis (plaque buildup in arteries). The major risk factors are smoking, diabetes, high blood pressure, and high cholesterol. Other contributing factors include obesity, physical inactivity, and age (especially over 50). A family history of cardiovascular disease also increases the risk of developing PAD, as does a diet high in saturated fats.
Peripheral Arterial Disease (PAD) is primarily caused by atherosclerosis, where fatty plaques build up in the arteries, leading to narrowing and reduced blood flow to the extremities, especially the legs. The process begins with endothelial dysfunction, allowing LDL cholesterol to accumulate and form plaques. As plaques grow, they restrict blood flow, causing ischemia and symptoms like intermittent claudication (leg pain during exercise). In advanced stages, plaque rupture can lead to blood clots, worsening blockages, and complications such as critical limb ischemia, non-healing ulcers, and gangrene. PAD is also linked to a higher risk of heart attack and stroke.

Peripheral Arterial Disease (PAD) is diagnosed through a combination of patient history, physical examination, and specific tests. The primary test is the Ankle-Brachial Index (ABI), which compares blood pressure in the ankle with blood pressure in the arm to assess blood flow. Other diagnostic tools include Doppler ultrasound to visualize blood flow in the arteries, and angiography (CT or MRI) to detect blockages. In some cases, blood tests may be done to check for cholesterol and diabetes, which are PAD risk factors.

Peripheral Arterial Disease (PAD) treatment focuses on improving blood flow, managing symptoms, and reducing the risk of complications like heart attack or stroke. Lifestyle changes are key, including quitting smoking, regular exercise, and a heart-healthy diet. Medications may be prescribed to control cholesterol, blood pressure, and blood sugar, along with blood thinners to prevent clots.

In more severe cases, procedures like angioplasty (to widen narrowed arteries), stenting, or bypass surgery may be required to restore blood flow. Regular follow-ups are essential to manage the condition long-term. If left untreated, PAD can lead to serious complications such as critical limb ischemia (severe pain and sores) and increase the risk of heart attack and stroke due to underlying cardiovascular disease.

"Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease (PAD) pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease (PAD) treatment guidelines.

The assessment part of the report embraces, in depth Peripheral Arterial Disease (PAD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease (PAD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease (PAD) R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease (PAD).

Peripheral Arterial Disease (PAD) Emerging Drugs Chapters

This segment of the Peripheral Arterial Disease (PAD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral Arterial Disease (PAD) Emerging Drugs

Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.

ACP 01: Hemostemix

ACP-01 is Hemostemix’s lead product, designed as an autologous cell therapy for regenerating damaged tissues in patients with critical limb ischemia (CLI) and other vascular diseases. The treatment uses the patient’s own stem cells, specifically angiogenic cell precursors (ACPs), which are harvested, processed, and then re-injected into areas of poor circulation.

These ACPs promote the growth of new blood vessels, aiming to restore blood flow and prevent amputations. ACP-01 has received orphan drug designation from the FDA and has shown promise in clinical trials, particularly for patients with no alternative treatment options. Currently, the drug is in the Phase II stage of its development for the treatment of Peripheral Arterial Disease.

Revacept: AdvanceCor

Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.

Peripheral Arterial Disease (PAD): Therapeutic Assessment

This segment of the report provides insights about the different Peripheral Arterial Disease (PAD) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral Arterial Disease (PAD)

There are approx. 20+ key companies which are developing the therapies for Peripheral Arterial Disease (PAD). The companies which have their Peripheral Arterial Disease (PAD) drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.

Phases

The report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peripheral Arterial Disease (PAD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Arterial Disease (PAD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease (PAD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease (PAD) drugs.

Peripheral Arterial Disease (PAD) Report Insights

• Peripheral Arterial Disease (PAD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral Arterial Disease (PAD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral Arterial Disease (PAD) drugs?
• How many Peripheral Arterial Disease (PAD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease (PAD)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease (PAD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peripheral Arterial Disease (PAD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AdvanceCor
• Novo Nordisk
• Hemostemix
• Helixmith
• Aplagon
• Vasa Therapeutics
• IsomAb

Key Products

• Revacept
• Semaglutide
• ACP 01
• VM202
• APAC
• VS 367
• ISM-001

This product will be delivered within 1-3 business days.